Jury awards Merck $2.5B in Gilead patent dispute

A federal jury ordered Gilead Sciences Inc. (NASDAQ:GILD) to pay Merck & Co. Inc. (NYSE:MRK) $2.5 billion in damages in an

Read the full 215 word article

User Sign In